|The DAF n/a (Catalog #MBS584669) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The DAF, Human, mAb 1C6 reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s DAF can be used in a range of immunoassay formats including, but not limited to, Flow Ctometry (FC/FACS), Functional Studies (FS), Immuno Assay (IA), Western Blot (WB).
For flow cytometry and Western blotting, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, in vitro dilutions have to be optimized in user\'s experimental setting.. Researchers should empirically determine the suitability of the DAF n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
The monoclonal antibody 1C6 recognizes human complement decay-accelerating factor (DAF), also designated as CD55. Cells express on their surface several proteins which protect against complement attack, namely complement receptor I (CR1), decay-accelerating factor (DAF), membrane cofactor protein (MCP) and CD59. CR1, DAF and MCP regulate the activation pathways of complement by either accelerating decay of the C3 and C5 convertase (CR1, DAF), or acting as cofactors for the serine protease factor I, which cleaves and irreversibly inactivates C3b (CR1, MCP).
Human DAF (CD55) is a protein of 381 amino acids resulting in a ~ 60 kDa transmembrane protein that binds C3b and C4b to inhibit formation and half-life of the C3 convertases. It belongs to the receptors of complement activation (RCA) family. DAF is broadly distributed among cells in contact with plasma complment proteins, including both haematopoietic and non-haematopoietic cells. Although DAF does not have an essential role in controling hemolysis of erythrocytes, it has an important role in regulation of the deposition of C3 on nucleated cells.
Together with other complement regulators DAF protects self cells from autologous complement-mediated injury. DAF cooperates with CD46 in circumventing autologous C3 deposition, while CD59 inhibits the pathway at the critical end-point. DAF is overexpressed in certain tumors thereby limiting the complement-dependent cytotoxiticy of therapeutic anticancer antibodies. Using DAF blocking antibodies targeted specifically at cancer cells in combination with immunotherapeutic monoclonal antibodies of cancer may improve the therapeutic effect in cancer patients. .
Immunogen: Purified DAF from pooled human erythrocyte stroma. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing DAF are readily searchable from our website. Different antibodies against the same target such as DAF may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.